Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Three studies totaling 31 COVID-19 cases in subjects on B cell depletion therapy reported all cases resolved without intensive care.
“Three studies, with a total of 31 COVID-19 cases, of subjects on B cell depletion therapy reported all COVID-19 cases resolved without intensive care (Montero-Escribano et al., 2020; Novi et al., 2020; Safavi et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Montero-Escribano et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Chan, J., Yuan, S.-F., Kok, K.-H., To, K., Chu, H., Yang, J., Xing, F., Liu, J.-L., Yip, C., Poon, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,450 · see citing works
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover
Soresina, A., Moratto, D., Chiarini, M., Paolillo, C., Baresi, G., Focà, E., Bezzi, M., Baronio, B., Giacomelli, M., & Badolato, R. (2020) · Pediatric Allergy and Immunology · doi:10.1111/pai.13263 · Cited by 327 · see citing works
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
Quinti, I., Lougaris, V., Milito, C., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.013 · Cited by 320 · see citing works
Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients.
Burks, J., Devald, B., Jankovsky, L., & Gerdes, J. (1980) · Science · doi:10.1126/science.7403860 · Cited by 231 · see citing works
The COVID-19 pandemic and the use of MS disease-modifying therapies
Giovannoni, G., Hawkes, C., Lechner‐Scott, J., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102073 · Cited by 191 · see citing works
An Italian programme for COVID-19 infection in multiple sclerosis
Sormani, M. P. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30147-2 · Cited by 189 · see citing works
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Novi, G., Mikulska, M., Briano, F., Toscanini, F., Tazza, F., Uccelli, A., & Inglese, M. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102120 · Cited by 162 · see citing works
¿Es esperable que haya cuadros neurológicos por la pandemia por SARS-CoV-2?
Matías-Guiu, J., Gómez‐Pinedo, U., Montero‐Escribano, P., Iglesias, P. G., Porta-Etessam, J., & Matias-Guiu, J. A. (2020) · Neurología · doi:10.1016/j.nrl.2020.03.001 · Cited by 110 · see citing works
Self-citationShould we expect neurological symptoms in the SARS-CoV-2 epidemic?
Matías‐Guiu, J., Gómez‐Pinedo, U., Montero‐Escribano, P., Iglesias, P. G., Porta-Etessam, J., & Matias-Guiu, J. A. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.03.002 · Cited by 99 · see citing works
Self-citationLa gestión de la asistencia neurológica en tiempos de la pandemia de Covid-19
Matías‐Guiu, J., Porta-Etessam, J., Valdés, E. L., García‐Morales, I., Guerrero-Sola, A., & Matias-Guiu, J. A. (2020) · Neurología · doi:10.1016/j.nrl.2020.04.001 · Cited by 60 · see citing works
Self-citationAnti-CD20 immunosuppressive disease-modifying therapies and COVID-19
Giovannoni, G. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102135 · Cited by 51 · see citing works
Management of neurological care during the COVID-19 pandemic
Matías-Guiu, J., Porta-Etessam, J., Valdés, E. L., García‐Morales, I., Guerrero-Sola, A., & Matias-Guiu, J. A. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.04.001 · Cited by 15 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860 · see citing works
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., & Amor, S. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13495 · Cited by 192 · see citing works
SARS-CoV-2-specific T cells in infection and vaccination
Bertoletti, A., Le Bert, N., Qui, M., & Tan, A. T. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00743-3 · Cited by 159 · see citing works
- Authors
- Montero-Escribano, P., Matías-Guiu, J., Gómez-Iglesias, P., Porta-Etessam, J., Pytel, V., & Matias-Guiu, J. A.
- Affiliations
- Universidad Complutense de Madrid (ES)
- Venue
- Multiple Sclerosis and Related Disorders
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 42
- Pages
- 102185
- ISSN
- 2211-0348 (ISSN-L)
- PMC
- PMC7204643
- OpenAlex
- W3022631642
- Cited by
- 128
- References
- 12
- Citations by year
- 2026: 1 · 2024: 5 · 2023: 8 · 2022: 27 · 2021: 46 · 2020: 41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Multiple Sclerosis and Related Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, multiple sclerosis, anti-CD20 therapy, ocrelizumab, immunosuppression, disease-modifying therapy, COVID-19 severity, COVID-19 complications, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, relapse rate, disability progression, treatment discontinuation
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Humans, Multiple Sclerosis, Pneumonia, Viral, Spain, Coronavirus Infections, Pandemics, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
